US2012172432A1PendingUtilityA1

Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same

65
Assignee: MANKU MEHARPriority: Apr 29, 2009Filed: Mar 13, 2012Published: Jul 5, 2012
Est. expiryApr 29, 2029(~2.8 yrs left)· nominal 20-yr term from priority
Inventors:Mehar MankuJonathan Rowe
A61P 9/10A61P 9/04A61P 3/08A61P 9/06A61P 9/00A61P 9/12A61P 7/02A61P 3/10A61P 7/12A61P 31/18A61P 3/04A61P 3/00A61P 25/28A61P 1/16A61K 31/405A61K 31/22A61K 31/505A61K 31/155A61K 31/222A61K 31/40A61K 47/34A61K 31/202A61K 31/47A61K 31/232A61K 31/366A61K 9/48A61K 31/337A61K 47/22A61K 2121/00A61P 3/06A61K 47/26A61K 31/397A61K 31/74A61K 45/06A61K 9/127A61K 9/4858A61K 9/20
65
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to, inter alia, pharmaceutical compositions comprising EPA and one or more cardiovascular agents, and to therapeutic methods for treating various diseases and disorders using the same.

Claims

exact text as granted — not AI-modified
1 . A method of treating a subject having baseline fasting triglycerides of at least 2000 mg/dl comprising, administering to the subject about 1 g to about 10 g per day of a pharmaceutical composition comprising at least 96% by weight ethyl eicosapentaenoate for a period effective to reduce fasting triglycerides in the subject without substantially increasing LDL-C relative to a control subject not taking said pharmaceutical composition. 
     
     
         2 . The method of  claim 1  wherein said period is a period effective to reduce fasting triglycerides in the subject by at least 50% without substantially increasing LDL-C relative to a control subject not taking said pharmaceutical composition. 
     
     
         3 . The method of  claim 1  wherein said period is a period effective to reduce fasting triglycerides in the subject by at least 55% without substantially increasing LDL-C relative to a control subject not taking said pharmaceutical composition. 
     
     
         4 . The method of  claim 1  wherein said period is about 1 to about 12 weeks. 
     
     
         5 . The method of  claim 1  wherein said period is 12 weeks. 
     
     
         6 . The method of  claim 1  wherein 2 g per day of the pharmaceutical composition is administered to the subject. 
     
     
         7 . The method of  claim 1  wherein 4 g per day of the pharmaceutical composition is administered to the subject. 
     
     
         8 . The method of  claim 1  wherein the composition is administered to the subject 1 to 4 times per day. 
     
     
         9 . The method of  claim 8  wherein the composition is present in one or more capsules.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.